Application-Delivered Patient Education in Enhancing the Usage of Apixaban in Patients With Atrial Fibrillation

Launched by YONSEI UNIVERSITY · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how using a mobile app to educate patients about their medication can help improve the use of apixaban, a blood thinner, in people with atrial fibrillation (AF). Atrial fibrillation is a common heart rhythm problem that can lead to serious issues like strokes if not managed properly. The trial will involve adults aged 19 and older who have non-valvular atrial fibrillation and are prescribed apixaban. Participants will be randomly assigned to either a group that receives education through the app or a group that does not receive this education.

If you join the study, you can expect to use the mobile app, which will provide helpful information about your treatment and how to take your medication correctly. The main goal is to see if this app-based education leads to fewer serious health events, such as strokes or major bleeding, compared to those who don’t use the app. It's important to note that potential participants should be able to use the mobile application and must be willing to provide consent to join the study. This trial aims to improve care for patients with atrial fibrillation by using technology to enhance understanding and adherence to medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 19 years or older with non-valvular atrial fibrillation (NVAF).
• • Willingness to provide informed consent and participate in the study.
• • Receiving Elxaban as anticoagulation therapy.
• • Ability to use the mobile application.
• Exclusion Criteria:
• • Inability to understand the study or refusal to provide consent.
• • Minors under 19 years of age.
• • Pregnant or breastfeeding women.
• • Conditions requiring chronic anticoagulation therapy other than atrial fibrillation (e.g., mechanical heart valve replacement).
• • Life expectancy of less than one year due to severe comorbid conditions.
• * Contraindications to Elxaban use, including:
• • 1. Hypersensitivity to the active ingredient or any excipients of the drug.
• • 2. Severe renal impairment (CrCL \<15 mL/min).
• • 3. Clinically significant active bleeding.
• 4. Increased bleeding risk due to the following conditions:
• • Recent history of gastrointestinal ulcer.
• • High-risk malignant neoplasms.
• • Recent brain or spinal cord injury.
• • Recent history of brain, spinal, or ophthalmic surgery.
• • Recent history of intracranial or cerebral hemorrhage.
• • Suspected or confirmed esophageal varices.
• • Arteriovenous malformations.
• • Vascular aneurysms.
• • Spinal or intracranial vascular abnormalities.